

Colony forming x100(%)
10
1
0.1
0.01
LNCaP (ETS-positve)
(n=3)
Compound 1
Olaparib
0 0.1 0.3 1 3 10 30
μM
PC3 (ETS-negative)
Compound 1
Olaparib
1 DMSO
0.3 10μM
0.1 3
3 DMSO
1 30μM
0.3 10

FIG. 1A



1.4
1.2
1
0.8
0.6
0.4
0.2
0
Relative Colony Number
10
100
1000
10000
Compound 1 [nM]
PC3
PC3-LACZ
PC3-ERG
PC3-EWS-FLI1
PC3-EWS-ERG
PC3-CRE8

FIG. 1B



1.2
1
0.8
0.6
0.4
0.2
0
Relative Colony Number
10
100
1000
10000
Compound 1 [nM]
VCaP
LNCaP
22RV1

FIG. 1C



ETS+
LNCaP
(PTEN−)
VCaP
(PTEN+)
ETS−
PC3
(PTEN−)
DU145
(PTEN+)
% Control
750
600
450
300
150
0
0.001
1
uM

FIG. 2



Method
DMSO
10μM Cmpd 1
10μM Olaparib
Pretreat 48h
48h
stain
LNCaP (ETS+)
DMSO
10μM Cmpd 1
10μM Olaparib
VCaP (ETS+)
DMSO
10μM Cmpd 1
PC3 (ETS−)
Serum Free (NC)
DMSO
10μM Cmpd 1
10μM Olaparib
DU1 45 (ETS−)
DMSO
10μM Cmpd 1

FIG. 3 (n=2)



Mock
0.1μM
0.33μM
1.0μM
3.33μM
10μM
Compound 1 [nM]
Relative COMET moment
40
35
30
25
20
15
10
5
0
**
**
**
22RV1
VCaP
LNCaP

FIG. 4



LNCaP-HR Tumor Volume
Vehicle (CMC-Tween)
MDV3100 (50 mg/kg, QD)
Compound 1 (1mg/kg QD)
Compound 1 (2mg/kg QD)
Compound 1 (5mg/kg QD)
*P<0.01
Tumor Volume (mm3)
3000
2500
2000
1500
1000
500
0
25
30
35
40
Days After Tumor Cell Inoculation
-32.0%
-37.4%
-60.3%
-61.5%

FIG. 5